108 related articles for article (PubMed ID: 27091549)
1. Reduced fibrillar β-amyloid in subcortical structures in a butyrylcholinesterase-knockout Alzheimer disease mouse model.
Darvesh S; Reid GA
Chem Biol Interact; 2016 Nov; 259(Pt B):307-312. PubMed ID: 27091549
[TBL] [Abstract][Full Text] [Related]
2. Butyrylcholinesterase-knockout reduces fibrillar β-amyloid and conserves
DeBay DR; Reid GA; Macdonald IR; Mawko G; Burrell S; Martin E; Bowen CV; Darvesh S
Brain Res; 2017 Sep; 1671():102-110. PubMed ID: 28729192
[TBL] [Abstract][Full Text] [Related]
3. Butyrylcholinesterase-knockout reduces brain deposition of fibrillar β-amyloid in an Alzheimer mouse model.
Reid GA; Darvesh S
Neuroscience; 2015 Jul; 298():424-35. PubMed ID: 25931333
[TBL] [Abstract][Full Text] [Related]
4. Interaction of Exogenous Butyrylcholinesterase with β-Amyloid Plaques in 5XFAD/Butyrylcholinesterase-Knockout Mouse Brain.
Reid GA; Darvesh S
Curr Alzheimer Res; 2021; 18(6):470-481. PubMed ID: 34455970
[TBL] [Abstract][Full Text] [Related]
5. Interaction of exogenous acetylcholinesterase and butyrylcholinesterase with amyloid-β plaques in human brain tissue.
Reid GA; Darvesh S
Chem Biol Interact; 2024 May; 395():111012. PubMed ID: 38648920
[TBL] [Abstract][Full Text] [Related]
6. Butyrylcholinesterase as a Diagnostic and Therapeutic Target for Alzheimer's Disease.
Darvesh S
Curr Alzheimer Res; 2016; 13(10):1173-7. PubMed ID: 27040140
[TBL] [Abstract][Full Text] [Related]
7. Quantification of Butyrylcholinesterase Activity as a Sensitive and Specific Biomarker of Alzheimer's Disease.
Macdonald IR; Maxwell SP; Reid GA; Cash MK; DeBay DR; Darvesh S
J Alzheimers Dis; 2017; 58(2):491-505. PubMed ID: 28453492
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal evaluation of a novel BChE PET tracer as an early
Rejc L; Gómez-Vallejo V; Joya A; Moreno O; Egimendia A; Castellnou P; Ríos-Anglada X; Cossío U; Baz Z; Passannante R; Tobalina-Larrea I; Ramos-Cabrer P; Giralt A; Sastre M; Capetillo-Zarate E; Košak U; Knez D; Gobec S; Marder M; Martin A; Llop J
Theranostics; 2021; 11(13):6542-6559. PubMed ID: 33995675
[No Abstract] [Full Text] [Related]
9. Immunohistochemical analysis of hippocampal butyrylcholinesterase: Implications for regional vulnerability in Alzheimer's disease.
Mizukami K; Akatsu H; Abrahamson EE; Mi Z; Ikonomovic MD
Neuropathology; 2016 Apr; 36(2):135-45. PubMed ID: 26293308
[TBL] [Abstract][Full Text] [Related]
10. Butyrylcholinesterase radioligands to image Alzheimer's disease brain.
Darvesh S
Chem Biol Interact; 2013 Mar; 203(1):354-7. PubMed ID: 22935510
[TBL] [Abstract][Full Text] [Related]
11. Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability.
Wright CI; Geula C; Mesulam MM
Ann Neurol; 1993 Sep; 34(3):373-84. PubMed ID: 8363355
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
Duysen EG; Li B; Darvesh S; Lockridge O
Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
[TBL] [Abstract][Full Text] [Related]
13. Electron microscopic localization of cholinesterase activity in Alzheimer brain tissue.
Carson KA; Geula C; Mesulam MM
Brain Res; 1991 Feb; 540(1-2):204-8. PubMed ID: 2054612
[TBL] [Abstract][Full Text] [Related]
14. Cholinesterases in normal and Alzheimer's disease primary olfactory gyrus.
Hamodat H; Cash MK; Fisk JD; Darvesh S
Neuropathol Appl Neurobiol; 2017 Dec; 43(7):571-583. PubMed ID: 28644906
[TBL] [Abstract][Full Text] [Related]
15. Butyrylcholinesterase in the life cycle of amyloid plaques.
Guillozet AL; Smiley JF; Mash DC; Mesulam MM
Ann Neurol; 1997 Dec; 42(6):909-18. PubMed ID: 9403484
[TBL] [Abstract][Full Text] [Related]
16. PTK2B/Pyk2 overexpression improves a mouse model of Alzheimer's disease.
Giralt A; de Pins B; Cifuentes-Díaz C; López-Molina L; Farah AT; Tible M; Deramecourt V; Arold ST; Ginés S; Hugon J; Girault JA
Exp Neurol; 2018 Sep; 307():62-73. PubMed ID: 29803828
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Preliminary Evaluation of Phenyl 4-123I-Iodophenylcarbamate for Visualization of Cholinesterases Associated with Alzheimer Disease Pathology.
Macdonald IR; Reid GA; Pottie IR; Martin E; Darvesh S
J Nucl Med; 2016 Feb; 57(2):297-302. PubMed ID: 26541777
[TBL] [Abstract][Full Text] [Related]
18. Neuropathology and cholinesterase expression in the brains of octogenarians and older.
Maxwell SP; Cash MK; Darvesh S
Chem Biol Interact; 2022 Sep; 364():110065. PubMed ID: 35872043
[TBL] [Abstract][Full Text] [Related]
19. Age-dependent association between butyrylcholinesterase K-variant and Alzheimer disease-related neuropathology in human brains.
Ghebremedhin E; Thal DR; Schultz C; Braak H
Neurosci Lett; 2002 Mar; 320(1-2):25-8. PubMed ID: 11849755
[TBL] [Abstract][Full Text] [Related]
20. Differential laminar distribution of acetylcholinesterase and butyrylcholinesterase containing tangles in the cerebral cortex of Alzheimer's disease.
Coleman AE; Geula C; Price BH; Mesulam MM
Brain Res; 1992 Nov; 596(1-2):340-4. PubMed ID: 1467998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
